Divi's Laboratories Crescita futura
Criteri Future verificati 3/6
Divi's Laboratories prevede che gli utili e i ricavi cresceranno rispettivamente di 17% e 15.5% all'anno. Si prevede che l'EPS crescerà di 17.1% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 18.9% in 3 anni.
Informazioni chiave
17.0%
Tasso di crescita degli utili
17.06%
Tasso di crescita dell'EPS
| Life Sciences crescita degli utili | 24.4% |
| Tasso di crescita dei ricavi | 15.5% |
| Rendimento futuro del capitale proprio | 18.92% |
| Copertura analitica | Good |
| Ultimo aggiornamento | 02 Jun 2026 |
Aggiornamenti recenti sulla crescita futura
Articolo di analisi • May 26
Divi's Laboratories Limited (NSE:DIVISLAB) Just Released Its Annual Results And Analysts Are Updating Their Estimates
Divi's Laboratories Limited ( NSE:DIVISLAB ) last week reported its latest yearly results, which makes it a good time...Articolo di analisi • Nov 11
Divi's Laboratories Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Divi's Laboratories Limited ( NSE:DIVISLAB ) just released its latest interim results and things are looking bullish...Articolo di analisi • Aug 10
Divi's Laboratories Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
NSEI:DIVISLAB 1 Year Share Price vs Fair Value Explore Divi's Laboratories's Fair Values from the Community and select...Articolo di analisi • Jul 17
Here's What Analysts Are Forecasting For Divi's Laboratories Limited (NSE:DIVISLAB) After Its Yearly Results
Divi's Laboratories Limited ( NSE:DIVISLAB ) shareholders are probably feeling a little disappointed, since its shares...Recent updates
Aggiornamento della narrazione • May 26
DIVISLAB: Elevated Future P/E Will Continue To Signal Overvaluation Risk
Analysts have lifted Divi's Laboratories price target from ₹5,133.17 to ₹5,333.98, citing updated assumptions on revenue growth, profit margins, and future P/E expectations. What's in the News A board meeting is scheduled for May 23, 2026, at 10:15 Indian Standard Time to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 (Key Developments).Articolo di analisi • May 26
Divi's Laboratories Limited (NSE:DIVISLAB) Just Released Its Annual Results And Analysts Are Updating Their Estimates
Divi's Laboratories Limited ( NSE:DIVISLAB ) last week reported its latest yearly results, which makes it a good time...Aggiornamento della narrazione • May 04
DIVISLAB: Elevated Future P/E Will Remain A Key Overvaluation Risk
Analysts have trimmed their price target on Divi's Laboratories slightly from ₹5,140 to about ₹5,133, reflecting updated assumptions around discount rates, revenue growth, profit margin, and future P/E expectations. Valuation Changes Fair Value: Trimmed slightly from ₹5,140.00 to about ₹5,133.17 per share.
Aggiornamento della narrazione • Apr 20
DIVISLAB: Upcoming Board Review Will Support Bullish Long Term Outlook
Analysts have lifted their price target for Divi's Laboratories slightly, with fair value now seen around ₹8,620 versus about ₹8,554 earlier, reflecting updated assumptions for discount rate, revenue growth, profit margin and future P/E. What's in the News A board meeting is scheduled on Feb 11, 2026 to consider and approve unaudited standalone financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).Aggiornamento della narrazione • Apr 05
DIVISLAB: Elevated Future P/E Will Persist Despite Unchanged Fair Value Estimate
Analysts have maintained Divi's Laboratories' fair value estimate at ₹5,140 per share, with only small tweaks to assumptions such as discount rate, revenue growth, profit margin, and future P/E, which together guide the latest price target narrative. What's in the News Board meeting scheduled for February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (Key Developments).
Aggiornamento della narrazione • Mar 22
DIVISLAB: Upcoming Board Review And Fair Value Update Signal Constructive Outlook
Analysts have made a small upward adjustment to the fair value estimate for Divi's Laboratories to around ₹6,875, reflecting slightly updated assumptions on the discount rate, revenue growth, profit margins and future P/E. What's in the News Board meeting scheduled on February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).Aggiornamento della narrazione • Mar 08
DIVISLAB: Rich Future P/E Will Persist Despite Softer Outlook After Results
Analysts have trimmed their price target on Divi's Laboratories from ₹5,290 to ₹5,140, reflecting updated assumptions around a slightly lower revenue growth outlook, a marginally higher profit margin, a modestly reduced future P/E multiple, and an adjusted discount rate. What's in the News A board meeting is scheduled for February 11, 2026 to review and approve unaudited standalone and consolidated financial results for the quarter ended December 31, 2025 (Key Developments).Aggiornamento della narrazione • Feb 22
DIVISLAB: Upcoming Results Review Will Shape Balanced Long Term Outlook
Narrative Update on Divi's Laboratories The analyst price target for Divi's Laboratories has been adjusted slightly higher from about ₹6,823 to roughly ₹6,870, with analysts pointing to small refinements in assumptions around discount rate, revenue growth, profit margin and future P/E as the drivers of this change. What's in the News A board meeting is scheduled for February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).Aggiornamento della narrazione • Feb 07
DIVISLAB: Upcoming Results Review Will Support Bullish Long Term Outlook
Analysts have lifted their price target on Divi's Laboratories slightly to ₹6,823 from about ₹6,785, citing refreshed assumptions around discount rates, revenue growth, profit margin and future P/E that remain broadly in line with prior views. What's in the News A board meeting is scheduled for February 11, 2026, to review and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Aggiornamento della narrazione • Jan 24
DIVISLAB: Management Changes And Rich Future P/E Will Sustain Excessive Optimism
Analysts now cite slightly higher assumptions on growth, profitability and future P/E in their models for Divi's Laboratories, which feeds into an updated fair value estimate of ₹5,290, compared with the previous ₹5,035.89. What's in the News Board meeting scheduled for November 7, 2025, at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).Aggiornamento della narrazione • Jan 10
DIVISLAB: Upcoming Board Review And Management Changes Will Support Bullish Outlook
Analysts have raised their price target for Divi's Laboratories from ₹7,750 to about ₹8,554, citing updated assumptions related to revenue growth, profit margins and future P/E levels in their models. What's in the News Board meeting scheduled on Nov 07, 2025 at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended Sep 30, 2025 (company filing).Articolo di analisi • Dec 30
Earnings Not Telling The Story For Divi's Laboratories Limited (NSE:DIVISLAB)
Divi's Laboratories Limited's ( NSE:DIVISLAB ) price-to-earnings (or "P/E") ratio of 68.3x might make it look like a...Aggiornamento della narrazione • Dec 25
DIVISLAB: Rising Profitability Expectations Will Mask Moderating Revenue And Justify Excessive Optimism
Analysts have raised their price target for Divi's Laboratories from ₹4,756 to ₹5,036, citing expectations of stronger profitability and a slightly richer future valuation multiple, despite moderating revenue growth assumptions. What's in the News Board meeting scheduled for November 7, 2025 at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).Aggiornamento della narrazione • Dec 11
DIVISLAB: Upcoming Board Meeting And Leadership Review Will Shape Fair Outlook
Analysts have nudged their price target for Divi's Laboratories slightly higher, reflecting marginal improvements in discount rate assumptions and long term growth expectations that together support a fair value estimate of ₹6,785.10 per share. What's in the News Board meeting scheduled for November 7, 2025, at 10:30 IST to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).Articolo di analisi • Dec 09
Divi's Laboratories (NSE:DIVISLAB) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Aggiornamento della narrazione • Nov 27
DIVISLAB: Upcoming Board Decisions And Modest Earnings Improvements Will Shape Outlook
Analysts have raised their fair value estimate for Divi's Laboratories from ₹6,433 to ₹6,785, citing modest improvements in revenue growth and profit margin expectations. What's in the News A board meeting is scheduled for November 7, 2025, at 10:30 IST to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Key Developments).Articolo di analisi • Nov 15
Investors Shouldn't Be Too Comfortable With Divi's Laboratories' (NSE:DIVISLAB) Earnings
Despite posting some strong earnings, the market for Divi's Laboratories Limited's ( NSE:DIVISLAB ) stock hasn't moved...Articolo di analisi • Nov 11
Divi's Laboratories Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Divi's Laboratories Limited ( NSE:DIVISLAB ) just released its latest interim results and things are looking bullish...Aggiornamento della narrazione • Nov 08
DIVISLAB: Upcoming Board Decisions And Modest Earnings Improvements Will Shape Outlook
Analysts have modestly increased their price target for Divi's Laboratories from ₹6,363 to ₹6,433, citing slight improvements in projected revenue growth and profit margins as the underlying factors. What's in the News Upcoming Board Meeting scheduled for November 7, 2025, at 10:30 AM IST.Articolo di analisi • Sep 06
Divi's Laboratories Limited's (NSE:DIVISLAB) Share Price Could Signal Some Risk
With a price-to-earnings (or "P/E") ratio of 69.2x Divi's Laboratories Limited ( NSE:DIVISLAB ) may be sending very...Aggiornamento della narrazione • Sep 05
Custom Synthesis And Capacity Expansion Will Unlock Global Demand
With both the consensus price target and future P/E ratio for Divi's Laboratories remaining virtually unchanged, analysts signal stable valuation expectations, resulting in a steady fair value assessment at ₹6363. What's in the News Board meeting scheduled to consider and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2025.Articolo di analisi • Aug 10
Divi's Laboratories Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
NSEI:DIVISLAB 1 Year Share Price vs Fair Value Explore Divi's Laboratories's Fair Values from the Community and select...Articolo di analisi • Aug 05
Most Shareholders Will Probably Agree With Divi's Laboratories Limited's (NSE:DIVISLAB) CEO Compensation
Key Insights Divi's Laboratories' Annual General Meeting to take place on 11th of August CEO Kiran Divi's total...Articolo di analisi • Jul 17
Here's What Analysts Are Forecasting For Divi's Laboratories Limited (NSE:DIVISLAB) After Its Yearly Results
Divi's Laboratories Limited ( NSE:DIVISLAB ) shareholders are probably feeling a little disappointed, since its shares...
Nuova narrazione • Nov 10
Tactical Expansions And Innovation Could Offset Generic Pricing Pressures And Boost Profitability
Strategic investments in peptide synthesis and greenfield expansion enhance future revenue potential through capacity and product line growth.Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 3/31/2029 | 170,330 | 43,083 | 19,169 | 42,752 | 11 |
| 3/31/2028 | 145,253 | 36,988 | 17,977 | 29,695 | 28 |
| 3/31/2027 | 122,739 | 30,293 | 11,124 | 24,458 | 29 |
| 3/31/2026 | 105,600 | 25,680 | 2,180 | 27,380 | N/A |
| 12/31/2025 | 103,140 | 24,790 | N/A | N/A | N/A |
| 9/30/2025 | 100,290 | 24,850 | 540 | 23,720 | N/A |
| 6/30/2025 | 96,520 | 23,060 | N/A | N/A | N/A |
| 3/31/2025 | 93,600 | 21,910 | 2,150 | 16,530 | N/A |
| 12/31/2024 | 90,780 | 20,670 | N/A | N/A | N/A |
| 9/30/2024 | 86,140 | 18,360 | 4,750 | 16,480 | N/A |
| 6/30/2024 | 81,850 | 16,740 | N/A | N/A | N/A |
| 3/31/2024 | 78,450 | 16,000 | 2,580 | 12,610 | N/A |
| 12/31/2023 | 74,926 | 13,834 | N/A | N/A | N/A |
| 9/30/2023 | 73,456 | 13,314 | 7,927 | 15,127 | N/A |
| 6/30/2023 | 72,906 | 14,774 | N/A | N/A | N/A |
| 3/31/2023 | 77,670 | 18,240 | 19,860 | 24,590 | N/A |
| 12/31/2022 | 83,353 | 23,971 | N/A | N/A | N/A |
| 9/30/2022 | 91,208 | 29,925 | 22,153 | 28,404 | N/A |
| 6/30/2022 | 92,538 | 31,054 | N/A | N/A | N/A |
| 3/31/2022 | 89,599 | 29,605 | 11,986 | 19,118 | N/A |
| 12/31/2021 | 82,297 | 25,678 | N/A | N/A | N/A |
| 9/30/2021 | 74,379 | 21,362 | 4,760 | 13,465 | N/A |
| 6/30/2021 | 71,996 | 20,493 | N/A | N/A | N/A |
| 3/31/2021 | 69,695 | 19,843 | 10,367 | 19,469 | N/A |
| 12/31/2020 | 65,710 | 18,705 | N/A | N/A | N/A |
| 9/30/2020 | 62,658 | 17,590 | 10,714 | 20,167 | N/A |
| 6/30/2020 | 59,620 | 15,962 | N/A | N/A | N/A |
| 3/31/2020 | 53,945 | 13,765 | 327 | 12,159 | N/A |
| 12/31/2019 | 52,719 | 12,803 | N/A | N/A | N/A |
| 9/30/2019 | 52,356 | 13,106 | N/A | 7,962 | N/A |
| 6/30/2019 | 51,139 | 13,575 | N/A | N/A | N/A |
| 3/31/2019 | 49,463 | 13,527 | N/A | 9,543 | N/A |
| 3/31/2018 | 38,915 | 8,770 | N/A | 7,759 | N/A |
| 3/31/2017 | 40,643 | 10,604 | N/A | 11,504 | N/A |
| 3/31/2016 | 37,764 | 11,258 | N/A | 10,379 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: La crescita prevista degli utili di DIVISLAB ( 17% all'anno) è superiore al tasso di risparmio ( 6.9% ).
Guadagni vs Mercato: Si prevede che gli utili di DIVISLAB ( 17% all'anno) cresceranno più rapidamente del mercato Indian ( 16.2% all'anno).
Guadagni ad alta crescita: Si prevede che gli utili di DIVISLAB cresceranno, ma non in modo significativo.
Ricavi vs Mercato: Si prevede che il fatturato di DIVISLAB ( 15.5% all'anno) crescerà più rapidamente del mercato Indian ( 10.8% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di DIVISLAB ( 15.5% all'anno) crescerà più lentamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Si prevede che il Return on Equity di DIVISLAB sarà basso tra 3 anni ( 18.9 %).
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/06 06:29 |
| Prezzo dell'azione a fine giornata | 2026/06/05 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2026/03/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Divi's Laboratories Limited è coperta da 47 analisti. 29 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Gaurav Tinani | Ambit Capital |
| Pranav Chawla | Ambit Capital |